Immunotherapy has become the standard first-line treatment of patients with dMMR/MSI-H mCRC, however, not all MSI-H CRC patients benefit from anti-PD-1, reported objective response rate (ORR) was about 40% (27, 28), suggesting the heterogeneity in patients with MSI-H. This evidence concerns the gene PDCD1 and colorectal carcinoma.